{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:55:37Z","timestamp":1780602937051,"version":"3.54.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2007]]},"DOI":"10.4158\/ep.13.5.550","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:55:24Z","timestamp":1365198924000},"page":"550-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Clinical Manifestations and Current Treatment options for Diabetic Neuropathies"],"prefix":"10.1016","volume":"13","author":[{"given":"Carolina M.","family":"Casellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP.13.5.550_bb0005","series-title":"Diabetes: Clinical Science in Practice","first-page":"221","article-title":"Epidemiology of the Complications of Diabetes","author":"Vinik","year":"1995"},{"key":"10.4158\/EP.13.5.550_bb0010","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/diacare.28.6.1480","article-title":"Underdiagnosis of peripheral neuropathy in type 2 diabetes","volume":"28","author":"Herman","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1056\/NEJM199409293311307","article-title":"Assessment and management of foot disease in patients with diabetes","volume":"331","author":"Caputo","year":"1994","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.13.5.550_bb0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The Development and validation of the Norfolk QOL-DN, a new measure of patients\u2019 perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 3","key":"10.4158\/EP.13.5.550_bb0025","first-page":"13","article-title":"Advances in diabetes for the millennium: new treatments for diabetic neuropathies","volume":"6","author":"Vinik","year":"2004","journal-title":"MedGenMed"},{"key":"10.4158\/EP.13.5.550_bb0030","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","article-title":"Diabetic somatic neuropathies","volume":"27","author":"Boulton","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0035","series-title":"Textbook of Diabetic Neuropathy","first-page":"170","article-title":"Severity and staging of diabetic polyneuropathy","author":"Dyck","year":"2003"},{"key":"10.4158\/EP.13.5.550_bb0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mcna.2004.04.009","article-title":"Diabetic Neuropathies","volume":"88","author":"Vinik","year":"2004","journal-title":"Med Clin North Am"},{"issue":"Suppl 2","key":"10.4158\/EP.13.5.550_bb0045","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.2337\/diab.46.2.S54","article-title":"Classification, differential diagnosis, and staging of diabetic peripheral neuropathy","volume":"46","author":"Thomas","year":"1997","journal-title":"Diabetes"},{"key":"10.4158\/EP.13.5.550_bb0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic Neuropathies: a statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0055","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1464-5491.2002.00801.x","article-title":"The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study","volume":"19","author":"Oyibo","year":"2002","journal-title":"Diabet Med"},{"key":"10.4158\/EP.13.5.550_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00418349","article-title":"Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis)","volume":"39","author":"Tesfaye","year":"1996","journal-title":"Diabetologia"},{"issue":"2","key":"10.4158\/EP.13.5.550_bb0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.nrl.0000156314.24508.ed","article-title":"Diabetic neuropathies. Classification, clinical features, and pathophysiological basis","volume":"11","author":"Sinnreich","year":"2005","journal-title":"Neurologist"},{"key":"10.4158\/EP.13.5.550_bb0070","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/diacare.16.11.1446","article-title":"Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population","volume":"16","author":"Harris","year":"1993","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0075","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mus.1136","article-title":"Painful Sensory Polyneuropathy Associated with Impaired Glucose Tolerance","volume":"24","author":"Singleton","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.4158\/EP.13.5.550_bb0080","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/diacare.24.8.1448","article-title":"Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy","volume":"24","author":"Singleton","year":"2001","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0085","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.57.9.1701","article-title":"Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy","volume":"57","author":"Smith","year":"2001","journal-title":"Neurology"},{"key":"10.4158\/EP.13.5.550_bb0090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1212\/WNL.60.1.108","article-title":"The spectrum of neuropathy in diabetes and impaired glucose tolerance","volume":"60","author":"Sumner","year":"2003","journal-title":"Neurology."},{"issue":"Suppl 1","key":"10.4158\/EP.13.5.550_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0021-9290(93)90077-R","article-title":"Ulceration, unsteadiness, and uncertainty: the biomechanical consequences of diabetes mellitus","volume":"26","author":"Cavanagh","year":"1993","journal-title":"J Biomech"},{"key":"10.4158\/EP.13.5.550_bb0100","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/diacare.20.12.1904","article-title":"Gait abnormalities in diabetic neuropathy","volume":"20","author":"Katoulis","year":"1997","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0105","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study [erratum in Neurology. 1993;43:2345]","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"key":"10.4158\/EP.13.5.550_bb0110","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archneur.59.5.758","article-title":"Demyelinating neuropathy in diabetes mellitus","volume":"59","author":"Sharma","year":"2002","journal-title":"Arch Neurol"},{"key":"10.4158\/EP.13.5.550_bb0115","series-title":"Ellenberg & Rifkin\u2019s Diabetes Mellitus","first-page":"789","article-title":"Diabetic autonomic neuropathy","author":"Vinik","year":"2003"},{"key":"10.4158\/EP.13.5.550_bb0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.106.634949","article-title":"Diabetic cardiovascular autonomic neuropathy","volume":"115","author":"Vinik","year":"2007","journal-title":"Circulation"},{"key":"10.4158\/EP.13.5.550_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.880110106","article-title":"Detection, characterization, and staging of poly-neuropathy: assessed in diabetes","volume":"11","author":"Dyck","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.4158\/EP.13.5.550_bb0130","first-page":"505","article-title":"Diabetic peripheral neuropathy: how reliable is a homemade 1-g monofilament for screening?","volume":"55","author":"Bourcier","year":"2006","journal-title":"J Fam Pract"},{"key":"10.4158\/EP.13.5.550_bb0135","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mus.880180603","article-title":"Quantitative measurement of cutaneous perception in diabetic neuropathy","volume":"18","author":"Vinik","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.4158\/EP.13.5.550_bb0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1464-5491.2002.00698.x","article-title":"The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort","volume":"19","author":"Abbott","year":"2002","journal-title":"Diabet Med"},{"issue":"Suppl 2","key":"10.4158\/EP.13.5.550_bb0145","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diab.46.2.S5","article-title":"Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study","volume":"46","author":"Dyck","year":"1997","journal-title":"Diabetes"},{"key":"10.4158\/EP.13.5.550_bb0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)90239-9","article-title":"Thermal testing: normative data and repeatability for various test algorithms","volume":"125","author":"Yarnitsky","year":"1994","journal-title":"J Neurol Sci"},{"key":"10.4158\/EP.13.5.550_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2337\/diacare.11.7.592","article-title":"Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy","volume":"11","author":"American Diabetes Association, American Academy of Neurology","year":"1988","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0160","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.410380323","article-title":"Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society","volume":"38","author":"Peripheral Nerve Society","year":"1995","journal-title":"Ann Neurol"},{"key":"10.4158\/EP.13.5.550_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199507133330203","article-title":"Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"Partanen","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.5.550_bb0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-122-8-199504150-00001","article-title":"The effect of intensive diabetes therapy on the development and progression of neuropathy","volume":"122","author":"The Diabetes Control and Complications Trial Research Group","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP.13.5.550_bb0175","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/diacare.27.7.1783","article-title":"Focal entrapment neuropathies in diabetes","volume":"27","author":"Vinik","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0180","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/WNL.47.4.1042","article-title":"Quantitation of epidermal nerves in diabetic neuropathy","volume":"47","author":"Kennedy","year":"1996","journal-title":"Neurology"},{"key":"10.4158\/EP.13.5.550_bb0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/152091501750219994","article-title":"Skin biopsy as a tool to assess distal small fiber innervation in diabetic neuropathy","volume":"3","author":"Polydefkis","year":"2001","journal-title":"Diabetes Technol Ther"},{"key":"10.4158\/EP.13.5.550_bb0190","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/diacare.27.8.1974","article-title":"Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients","volume":"27","author":"Pittenger","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0195","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"29","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0200","unstructured":"Rice A, Barlow P, Pittenger G, Simmons K, Vinik A. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with diabetes. Diabetes Care. In press."},{"key":"10.4158\/EP.13.5.550_bb0205","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2337\/diacare.26.9.2549","article-title":"The development and validation of a neuropathy- and foot ulcer-Specific quality of life instrument","volume":"26","author":"Vileikyte","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0210","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.5.550_bb0215","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [erratum in BMJ. 1999;318:29]","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.4158\/EP.13.5.550_bb0220","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [erratum in Lancet. 1998:352:1558]","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.4158\/EP.13.5.550_bb0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.5.550_bb0230","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.5.550_bb0235","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ana.20295","article-title":"C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes","volume":"56","author":"Kamiya","year":"2004","journal-title":"Ann Neurol"},{"key":"10.4158\/EP.13.5.550_bb0240","doi-asserted-by":"crossref","first-page":"E497","DOI":"10.1152\/ajpendo.00048.2004","article-title":"C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB\/Wor rats","volume":"287","author":"Stevens","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP.13.5.550_bb0245","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2337\/diabetes.52.2.536","article-title":"Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes","volume":"52","author":"Ekberg","year":"2003","journal-title":"Diabetes"},{"key":"10.4158\/EP.13.5.550_bb0250","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF00418540","article-title":"C-peptide improves autonomic nerve function in IDDM patients","volume":"39","author":"Johansson","year":"1996","journal-title":"Diabetologia"},{"key":"10.4158\/EP.13.5.550_bb0255","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2337\/dc06-1274","article-title":"C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy","volume":"30","author":"Ekberg","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0260","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.2337\/diacare.27.9.2178","article-title":"Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy","volume":"27","author":"Ziegler","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0265","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.0.1340467","article-title":"Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats","volume":"134","author":"Miyauchi","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP.13.5.550_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5414\/CPP43071","article-title":"Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) [erratum in Int J Clin Pharmacol Ther. 2005;43:304]","volume":"43","author":"Haupt","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.4158\/EP.13.5.550_bb0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0029-1211460","article-title":"A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy","volume":"104","author":"Stracke","year":"1996","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.4158\/EP.13.5.550_bb0280","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/diacare.27.10.2369","article-title":"Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy","volume":"27","author":"Bril","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0285","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2337\/diacare.29.01.06.dc05-1447","article-title":"Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy","volume":"29","author":"Bril","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/diacare.16.1.8","article-title":"Treatment of diabetic neuropathy with gamma-linolenic acid","volume":"16","author":"Keen","year":"1993","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.13.5.550_bb0295","first-page":"770","article-title":"The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial [erratum in Diabetes Care. 2003;26:2227]","volume":"26","author":"Ametov","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0300","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1046\/j.1464-5491.1999.00190.x","article-title":"Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy","volume":"16","author":"Ruhnau","year":"1999","journal-title":"Diabet Med"},{"key":"10.4158\/EP.13.5.550_bb0305","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"key":"10.4158\/EP.13.5.550_bb0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10715769900300721","article-title":"Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)","volume":"31","author":"Reljanovic","year":"1999","journal-title":"Free Radic Res"},{"key":"10.4158\/EP.13.5.550_bb0315","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1464-5491.2004.01109.x","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis","volume":"21","author":"Ziegler","year":"2004","journal-title":"Diabet Med"},{"key":"10.4158\/EP.13.5.550_bb0320","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0325","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.clinthera.2005.08.001","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year randomized, placebo-controlled, double-blind clinical trial","volume":"27","author":"Vinik","year":"2005","journal-title":"Clin Ther"},{"key":"10.4158\/EP.13.5.550_bb0330","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/mus.20423","article-title":"Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy","volume":"32","author":"Vinik","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.4158\/EP.13.5.550_bb0335","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/dc06-1699","article-title":"A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy","volume":"30","author":"Casellini","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0340","first-page":"271","article-title":"Nerve growth factor and diabetic neuropathy","volume":"4","author":"Pittenger","year":"2003","journal-title":"Exp Diabesity Res"},{"issue":"Suppl 1","key":"10.4158\/EP.13.5.550_bb0345","first-page":"A54","article-title":"Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve growth factor (rhNGF)","volume":"48","author":"Vinik","year":"1999","journal-title":"Diabetes"},{"key":"10.4158\/EP.13.5.550_bb0350","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0002-9440(10)65282-0","article-title":"Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF","volume":"154","author":"Rivard","year":"1999","journal-title":"Am J Pathol"},{"key":"10.4158\/EP.13.5.550_bb0355","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1096\/fj.04-1894fje","article-title":"INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL\/6 mice","volume":"18","author":"Tam","year":"2004","journal-title":"FASEB J"},{"key":"10.4158\/EP.13.5.550_bb0360","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s001250050834","article-title":"Anti-ganglioside GM1 antibody and distal symmetric \u201cdiabetic polyneuropathy\u201d with dominant motor features","volume":"40","author":"Milicevic","year":"1997","journal-title":"Diabetologia"},{"key":"10.4158\/EP.13.5.550_bb0365","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2337\/diacare.28.8.1959","article-title":"Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy","volume":"28","author":"Granberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0370","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2337\/diacare.28.8.2067","article-title":"Antibodies to neuronal structures: innocent bystanders or neurotoxins?","volume":"28","author":"Vinik","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP.13.5.550_bb0375","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archneur.1995.00540350039015","article-title":"Successful treatment of neuropathies in patients with diabetes mellitus","volume":"52","author":"Krendel","year":"1995","journal-title":"Arch Neurol"},{"key":"10.4158\/EP.13.5.550_bb0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00002512-199507040-00007","article-title":"Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis","volume":"7","author":"Rains","year":"1995","journal-title":"Drugs Aging"},{"key":"10.4158\/EP.13.5.550_bb0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain"},{"key":"10.4158\/EP.13.5.550_bb0390","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"10.4158\/EP.13.5.550_bb0395","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pain.2006.09.040","article-title":"Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies","volume":"128","author":"Vinik","year":"2007","journal-title":"Pain"},{"key":"10.4158\/EP.13.5.550_bb0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s004150050179","article-title":"Uncommon early-onset neuropathy in diabetic patients","volume":"245","author":"Said","year":"1998","journal-title":"J Neurol"},{"key":"10.4158\/EP.13.5.550_bb0405","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.50.6.1842","article-title":"Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy","volume":"50","author":"Harati","year":"1998","journal-title":"Neurology"},{"key":"10.4158\/EP.13.5.550_bb0410","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archneur.60.11.1524","article-title":"Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations","volume":"60","author":"Dworkin","year":"2003","journal-title":"Arch Neurol"},{"key":"10.4158\/EP.13.5.550_bb0415","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0304-3959(90)91157-E","article-title":"The selective serotonin reuptake inhibitor paroxetine is effective in treatment of diabetic neuropathy symptoms","volume":"42","author":"Sindrup","year":"1990","journal-title":"Pain"},{"key":"10.4158\/EP.13.5.550_bb0420","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1526-4637.2006.00207.x","article-title":"Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study","volume":"7","author":"Raskin","year":"2006","journal-title":"Pain Med"},{"key":"10.4158\/EP.13.5.550_bb0425","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pain.2004.05.010","article-title":"Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [erratum in Pain. 2005;113:248]","volume":"110","author":"Rowbotham","year":"2004","journal-title":"Pain"},{"issue":"21","key":"10.4158\/EP.13.5.550_bb0430","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"10.4158\/EP.13.5.550_bb0435","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00007691-199708000-00006","article-title":"Changes in body weight with chronic, high-dose gabapentin therapy","volume":"19","author":"DeToledo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.4158\/EP.13.5.550_bb0440","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multi-centre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"10.4158\/EP.13.5.550_bb0445","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain"},{"key":"10.4158\/EP.13.5.550_bb0450","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2165\/00003495-200464240-00006","article-title":"Pregabalin: in the treatment of painful diabetic peripheral neuropathy","volume":"64","author":"Frampton","year":"2004","journal-title":"Drugs"},{"key":"10.4158\/EP.13.5.550_bb0455","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.clinthera.2006.11.017","article-title":"Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective","volume":"28","author":"Tarride","year":"2006","journal-title":"Clin Ther"},{"key":"10.4158\/EP.13.5.550_bb0460","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/01.WNL.0000137341.89781.14","article-title":"Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects","volume":"63","author":"Raskin","year":"2004","journal-title":"Neurology"},{"key":"10.4158\/EP.13.5.550_bb0465","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1210\/jc.2004-2376","article-title":"Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy","volume":"90","author":"Vinik","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP.13.5.550_bb0470","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa042580","article-title":"Morphine, gabapentin, or their combination for neuropathic pain","volume":"352","author":"Gilron","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.13.5.550_bb0475","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.1992.tb01819.x","article-title":"Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus","volume":"9","author":"Cavanagh","year":"1992","journal-title":"Diabet Med"},{"key":"10.4158\/EP.13.5.550_bb0480","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1532-5415.2004.52200.x","article-title":"Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: a 6-month randomized, controlled trial","volume":"52","author":"Liu-Ambrose","year":"2004","journal-title":"J Am Geriatr Soc"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20420506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/P53M48300742H475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:44Z","timestamp":1761515324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20420506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"alternative-id":["S1530891X20420506"],"URL":"https:\/\/doi.org\/10.4158\/ep.13.5.550","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Manifestations and Current Treatment options for Diabetic Neuropathies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.13.5.550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}